Skip to main content

Rapport Therapeutics, Inc.

corporate_fare Company Profile

Rapport Therapeutics, Inc.

RAPP·NASDAQ·Life Sciences·CIK 0002012593

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The company's foundational science explores neuronal receptor biology, allowing it to identify and target specific neuronal receptor complexes. These complexes are made up of receptor principal subunits and receptor associated proteins (RAPs), which are important for regulating how receptors function and are expressed. Rapport Therapeutics believes its expertise in RAP biology allows it to target previously inaccessible areas and develop neurological and psychiatric drugs that are specific to certain receptor variants and brain regions linked to diseases. This specificity aims to reduce the undesired side effects often seen with most neuroactive drugs. The company is developing a portfolio of precision product candidates based on its RAP technology platform, which originated from its founders' discoveries about RAP function in the brain. This platform aims to overcome limitations of traditional neurology drug discovery. RAP-219 is Rapport Therapeutics' most advanced product candidate. It is an AMPA receptor (AMPAR) negative allosteric modulator (NAM). RAP-219 is designed to achieve neuroanatomical specificity by selectively targeting TARP  8, a RAP associated with neuronal AMPARs. While AMPARs are widely distributed in the central nervous system (CNS), TARP  8 is expressed only in specific regions like the neocortex and mesial temporal lobe, where focal onset seizures (FOS) often begin. TARP  8 has low expression in the hindbrain, a region often linked to adverse drug events. The company believes RAP-219 has the potential for a differentiated profile compared to traditional neuroscience medications.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for RAPP at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • 10% Shareholder Third Rock Ventures Files Intent to Sell Over $17M in Rapport Therapeutics Stock
  • Officer Files Intent to Sell $661K in Rapport Therapeutics Shares, Continuing Recent Selling Pattern
  • Rapport Therapeutics Files New $150M At-The-Market Offering to Fund Clinical Development
  • Rapport Therapeutics Advances Lead Candidate RAP-219 to Phase 3 with FDA Support, Secures Major China Partnership
  • Rapport Therapeutics Reports Strong Phase 2a FOS Data, Accelerates Phase 3, and Secures Strategic China Partnership

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$111.48M
Diluted EPS
-$2.86
Op. Cash Flow
-$87.47M
Free Cash Flow
-$88.09M
Operating Income
-$125.1M
Cash & Equivalents
$52.65M
Debt / Equity
0.00×
Shares Outstanding
47.77M sh
Source: 10-K · filed 2026-03-10 · accession 0001193125-26-099360
$23.16
52-week range · as of 2026-11-04 $22.06 – $52.93
Market cap
$1.37B
Volume
437.7K (0.4× avg)
3-mo avg 1.2M
Live data · 2026-11-22 06:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RAPP - Filings & News (Page 2)

RAPP
Apr 17, 2026, 4:25 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $39.71
Real-time Price: $23.16 info
Change: -$16.55 (-42%) info
Market Cap: $1.373B info
RAPP
Apr 13, 2026, 4:37 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $34.65
Real-time Price: $23.16 info
Change: -$11.49 (-33%) info
Market Cap: $1.373B info
RAPP
Mar 10, 2026, 8:16 AM EDT
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $31.01
Real-time Price: $23.16 info
Change: -$7.85 (-25%) info
Market Cap: $1.373B info
RAPP
Mar 10, 2026, 7:25 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $30.71
Real-time Price: $23.16 info
Change: -$7.55 (-25%) info
Market Cap: $1.373B info
RAPP
Mar 10, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $30.71
Real-time Price: $23.16 info
Change: -$7.55 (-25%) info
Market Cap: $1.373B info
RAPP
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.24
Real-time Price: $23.16 info
Change: -$7.08 (-23%) info
Market Cap: $1.373B info
RAPP
Jan 07, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.26
Real-time Price: $23.16 info
Change: -$4.10 (-15%) info
Market Cap: $1.373B info
RAPP
Jan 07, 2026, 8:23 AM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $30.12
Real-time Price: $23.16 info
Change: -$6.96 (-23%) info
Market Cap: $1.373B info
RAPP
Jan 07, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.12
Real-time Price: $23.16 info
Change: -$6.96 (-23%) info
Market Cap: $1.373B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets